The Abbreviated New Drug Application (ANDA) process is one of the hottest areas of intellectual property disputes among companies today. But the Federal Circuit’s recent decision in Tyco Healthcare v. Mutual Pharmaceutical is beginning to demonstrate that the intersection between intellectual property law and antitrust is growing. Martin Lueck, Partner and Chairman for Robins, Kaplan, Miller & Ciresi L.L.P., sits down with Seth Northrop to discuss the overlap and how it may impact ANDA cases going forward.
Press CTRL+C to copy embed code to clipboard